This systematic review maps the recent antidepressant landscape by identifying 15 FDA-approved medications for depressive disorders from 2009 through April 2025 and 18 pipeline medications in Phase 3 trials.

Read More> https://pocncoe.com/mdd/home/article/what-s-next-in-depression-treatment-new-approvals-and-phase-3-agents-to-watch/